At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Empagliflozin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo Controlled, Cross-over Renal Mechanistic Trial to Assess the Effect of Adding Empagliflozin Versus Placebo on Renal Hyperfiltration on a Background of the Angiotensin Converting Enzyme Inhibitor (ACEi) Ramipril: BETWEEN Study
In Brief
A Phase 2 clinical trial evaluating Empagliflozin, Placebo (matching empagliflozin), and 1 other intervention for Diabetes Mellitus, Type 1 and 2 related conditions. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartMay 2016
Primary CompletionDec 2017
Study CompletionJul 2019
TodayJul 2026
First PostedDec 17, 2015
Enrollment StartMay 10, 2016
Primary CompletionDec 19, 2017
Study CompletionJul 2, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.5 years ago
Interventions
Empagliflozindrug
Empagliflozin will be taken once daily
Placebo (matching empagliflozin)drug
Placebo will be taken once daily
ramiprildrug
Ramipril will be taken once or twice daily